Claims for Patent: 5,639,440

Summary for Patent: 5,639,440

Title:	Method for evaluating immunogenicity
Abstract:	Biological effects of agents for diagnostic or therapeutic use are evaluated by administration of the agents to transgenic animals which are transformed with heterologous DNA and which are immune tolerant to the expression product of the heterologous DNA. In a further embodiment, preparations that are immunogenic in the transgenic animal model are purified by reverse immunoaffinity chromatography on antibody obtained from responding transgenic animals.
Inventor(s):	Martin, Jr.; David W. (San Francisco, CA)
Assignee:
Application Number:	08/428,932
Patent Claims:	1. A method for separating an immunogenic component from a preparation comprising a polypeptide of interest and the immunogenic component comprising the steps of; (a) administering said preparation comprising said polypeptide of interest and said immunogenic component to a transgenic mammal whose somatic or germ cells contain a DNA sequence encoding said polypeptide of interest, said polypeptide being heterologous to said mammal and said mammal being immunologically tolerant to said polypeptide of interest as a result of the expression of said DNA sequence with the preparation comprising said polypeptide of interest and said immunogenic component; (b) obtaining from the transgenic mammal of step (a) antibody capable of binding said immunogenic component; (c) contacting the antibody of step (b) with the preparation comprising said polypeptide of interest and said immunogenic component under conditions to adsorb said immunogenic component from the preparation; and (d) separating said polypeptide of interest from the antibody-adsorbed immunogenic component. 2. The method of claim 1 wherein the antibody of step (b) is a monoclonal antibody. 3. The method of claim 1 wherein the antibody of step (b) is a polyclonal antibody. 4. The method of claim 1 wherein the antibody is insolubilized by cross-linking to a water insoluble matrix. 5. The method of claim 1 wherein the preparation comprising said polypeptide of interest is the supernatant from a recombinant cell culture expressing said polypeptide of interest. 6. The method of claim 5 wherein said polypeptide of interest is a human polypeptide and the transgenic mammal is a mouse. 7. The method of claim 1 wherein said immunogenic component is a denatured polypeptide of interest. 8. The method of claim 4 wherein said polypeptide of interest is separated from said antibody-adsorbed immunogenic component by washing from the insoluble matrix. 9. The method of claim 1 wherein the antibody is a plurality of monoclonal antibodies, each of which is capable of binding a different immunogenic component in the preparation comprising said polypeptide of interest. 10. The method of claim 1 wherein said polypeptide of interest is selected from the group consisting of human tissue plasminogen activator, human serum albumin, human growth hormone and human factor VIII. 11. The method of claim 10 wherein said polypeptide of interest is human serum albumin and the preparation comprising said polypeptide of interest is a human serum albumin-containing culture supernatant of a yeast transformed with DNA encoding human serum albumin.

Details for Patent 5,639,440

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2014-06-17
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2014-06-17
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2014-06-17